[Clinical comparative study of neoadjuvant chemotherapy outcome in locally advanced breast cancer: docetaxel versus paclitaxel plus pirarubicin hydrochloride and cyclophosphamide].

Abstract

OBJECTIVE:

To compare the efficacy and toxicity of neoadjuvant chemotherapy of docetaxel with paclitaxel plus pirarubicin hydrochloride (THP) and cyclophosphamide (CTX) in locally advanced breast cancer (LABC).

METHODS:

A total of 97 LABC cases were randomly divided into 2 groups: docetaxel group (n = 49, taxotere plus THP & CTX) and paclitaxel group (n = 48, paclitaxel plus THP & CTX). Neoadjuvant chemotherapy had four cycles of 21 days each.

RESULTS:

The clinical and pathological complete remission rates of docetaxel group was 28.6% and 26.5% respectively. They were significantly higher than those of paclitaxel group (10.4% and 8.3%). Furthermore the pathological negative rate of regional lymph node in docetaxel group was also significantly higher than that of paclitaxel group (40.6% vs. 12.9%). However, grade III-IV blood system toxic reaction was found in 71.4% cases, grade II-IV liver dysfunction in 53.1% cases and edema in 24.5% cases among docetaxel group. They were higher than those among paclitaxel group (46.9%, 27.1% & 4.2%).

CONCLUSION:

Compared with paclitaxel, the combined regimen of docetaxel plus THP and CTX offers better outcomes for locally advanced breast cancer.

• Authors: Jing Su, Meng-quan Li, Han Xu, Di Hu
• Journal: Zhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 91 Issue 26 Pg. 1837-9 (Jul 12 2011) ISSN: 0376-2491 [Print] China
• PMID: 22093786 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Taxoids
• Docetaxel
• Doxorubicin
• Cyclophosphamide
• pirarubicin
• Paclitaxel

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Cyclophosphamide (administration & dosage)
• Docetaxel
• Doxorubicin (administration & dosage, analogs & derivatives)
• Female
• Humans
• Middle Aged
• Neoplasm Staging
• Paclitaxel (administration & dosage)
• Taxoids (administration & dosage)
• Young Adult